{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:36:40Z","timestamp":1790012200460,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.amjcard.2005.03.004","type":"journal-article","created":{"date-parts":[[2005,4,20]],"date-time":"2005-04-20T07:28:41Z","timestamp":1113982121000},"page":"14-23","source":"Crossref","is-referenced-by-count":66,"special_numbering":"S1","title":["Current Treatments and Novel Pharmacologic Treatments for Hyponatremia in Congestive Heart Failure"],"prefix":"10.1016","volume":"95","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2005.03.004_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","article-title":"Vasopressin receptor antagonists in heart failure","volume":"3","author":"Thibonnier","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000441-200001000-00002","article-title":"Diuretic complications","volume":"319","author":"Greenberg","year":"2000","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjcard.2005.03.004_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1681\/ASN.V481522","article-title":"Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective","volume":"4","author":"Sterns","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJM198606123142402","article-title":"Osmotic demyelination syndrome following correction of hyponatremia","volume":"314","author":"Sterns","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-107-5-656","article-title":"Severe symptomatic hyponatremia: treatment and outcome","volume":"107","author":"Sterns","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(90)90517-H","article-title":"The treatment of hyponatremia: first, do no harm","volume":"88","author":"Sterns","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9343(96)00274-4","article-title":"Epidemiology, pathophysiology, and management of hyponatremic encephalopathy","volume":"102","author":"Fraser","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib9","first-page":"2387","article-title":"Management of hyponatremia","volume":"69","author":"Goh","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.amjcard.2005.03.004_bib10","series-title":"The edematous patient: cardiac failure, cirrhosis, and nephrotic syndrome","author":"Ellison","year":"2000"},{"key":"10.1016\/j.amjcard.2005.03.004_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3810\/pgm.2000.5.1.1068","article-title":"Hyponatremia and hypernatremia: a systematic approach to causes and their correction","volume":"107","author":"Fall","year":"2000","journal-title":"Postgrad Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.me.44.020193.001445","article-title":"Control of brain volume during hyperosmolar and hypoosmolar conditions","volume":"44","author":"Gullans","year":"1993","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.amjcard.2005.03.004_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0006-8993(91)90806-7","article-title":"Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats","volume":"567","author":"Verbalis","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.amjcard.2005.03.004_bib14","first-page":"3","article-title":"Adaptation to acute and chronic hyponatremia: implications for symptomatology, diagnosis, and therapy","volume":"18","author":"Verbalis","year":"1998","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib15","series-title":"Atlas of Diseases of the Kidney","first-page":"1.1","article-title":"Diseases of water metabolism","author":"Kumar","year":"1999"},{"key":"10.1016\/j.amjcard.2005.03.004_bib16","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.281.24.2299","article-title":"Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality","volume":"281","author":"Ayus","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2005.03.004_bib17","first-page":"197","article-title":"Diuretic therapy in congestive heart failure","volume":"6","author":"Brater","year":"2000","journal-title":"Congestive Heart Fail"},{"key":"10.1016\/j.amjcard.2005.03.004_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0735-1097(87)80278-4","article-title":"Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure","volume":"10","author":"Packer","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0889-8529(03)00004-5","article-title":"Evaluation and management of hypo-osmolality in hospitalized patients","volume":"32","author":"Janicic","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.amjcard.2005.03.004_bib20","series-title":"Diseases of the Kidney","first-page":"2393","article-title":"The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders","author":"Verbalis","year":"1996"},{"key":"10.1016\/j.amjcard.2005.03.004_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1067\/mhj.2003.166","article-title":"Effects.of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in.refractory congestive heart failure: long-term effects","volume":"145","author":"Licata","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2005.03.004_bib22","first-page":"288","article-title":"Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2005.03.004_bib23","series-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","article-title":"Diuretics","author":"Jackson","year":"1996757"},{"key":"10.1016\/j.amjcard.2005.03.004_bib24","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.1980.03300500039026","article-title":"Plasma demeclocycline levels and nephrotoxicity: correlation in hyponatremic cirrhotic patients","volume":"243","author":"Miller","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2005.03.004_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(99)00004-7","article-title":"Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells","volume":"368","author":"Tahara","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004240050772","article-title":"AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1a or V1b receptors","volume":"437","author":"Tahara","year":"1999","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.amjcard.2005.03.004_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2005.03.004_bib28","first-page":"852","article-title":"Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure","volume":"293","author":"Clair","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2005.03.004_bib29","doi-asserted-by":"crossref","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, for the Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690\u20132696.","DOI":"10.1161\/01.CIR.0000070422.41439.04"},{"key":"10.1016\/j.amjcard.2005.03.004_bib30","doi-asserted-by":"crossref","unstructured":"Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vaspressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963\u20131971.","DOI":"10.1001\/jama.291.16.1963"},{"key":"10.1016\/j.amjcard.2005.03.004_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjcard.2005.03.004_bib32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","article-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial","volume":"124","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjcard.2005.03.004_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2005.03.004_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1043661802002062","article-title":"Effect of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs","volume":"46","author":"Yatsu","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2005.03.004_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(99)00379-9","article-title":"Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure","volume":"376","author":"Yatsu","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib36","first-page":"301","article-title":"Pharmacological profile of YM087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2005.03.004_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(96)00940-5","article-title":"Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs","volume":"321","author":"Yatsu","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjcard.2005.03.004_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(97)00324-6","article-title":"Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte","volume":"38","author":"Tahara","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2005.03.004_bib39","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2005.03.004_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1067\/mhj.2003.39","article-title":"Rationale for use of an exercise end point and design for the ADVANCE (A Dose Evaluation of a Vasopressin Antagonist in CHF Patients Undergoing Exercise) trial","volume":"145","author":"Russell","year":"2003","journal-title":"Am Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914905003553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914905003553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T05:31:47Z","timestamp":1625808707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914905003553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0002914905003553"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2005.03.004","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}